美迪西涨2.05%，成交额3.12亿元，主力资金净流出1586.10万元

Company Overview - Shanghai Medicilon Inc. is located at 585 Chuan Da Road, Chuansha New Town, Pudong New District, Shanghai, and was established on February 2, 2004. The company was listed on November 5, 2019. Its main business involves providing comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [1]. Financial Performance - As of June 30, 2023, Medicilon achieved operating revenue of 540 million yuan, representing a year-on-year growth of 3.64%. The net profit attributable to the parent company was -12.89 million yuan, showing a year-on-year increase of 81.63% [2]. - The company has cumulatively distributed dividends of 158 million yuan since its A-share listing, with a total of 33.94 million yuan distributed over the past three years [3]. Stock Performance - On September 18, 2023, Medicilon's stock price increased by 2.05%, reaching 77.56 yuan per share, with a trading volume of 312 million yuan and a turnover rate of 3.05%. The total market capitalization stood at 10.42 billion yuan [1]. - Year-to-date, Medicilon's stock price has risen by 157.08%, with a 0.52% increase over the last five trading days, a 24.29% increase over the last 20 days, and a 126.25% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on July 17, 2023, where it recorded a net purchase of 102 million yuan [1]. Shareholder Information - As of June 30, 2023, Medicilon had 12,900 shareholders, an increase of 3.94% from the previous period. The average number of circulating shares per person was 10,443, a decrease of 3.79% from the previous period [2]. Industry Classification - Medicilon belongs to the pharmaceutical and biological industry, specifically in the medical services and medical research outsourcing sectors. It is associated with concepts such as CRO (Contract Research Organization), MSCI China, margin financing, mid-cap stocks, and specialized and innovative enterprises [2].